- £1.99bn
- £1.05bn
- $630.20m
- 23
- 44
- 41
- 24
RCS - Hutchmed China Ltd - China NDA Acceptance for ORPATHYS and TAGRISSO
AnnouncementREG - Hutchmed China Ltd - US$608m Divestment of Non-Core Joint Venture
AnnouncementREG - Hutchmed China Ltd - Overseas Regulatory Announcement
AnnouncementREG - Hutchmed China Ltd - Appointment of Joint Corporate Broker
AnnouncementREG - Hutchmed China Ltd - Blocklisting Six Monthly Return
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED to Receive Milestone Payment from Takeda
AnnouncementRCS - Hutchmed China Ltd - Breakthrough Therapy Designation in China
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED and Innovent Announce ELUNATE Approval
AnnouncementREG - Hutchmed China Ltd - Total Voting Rights
AnnouncementRCS - Hutchmed China Ltd - Continued Inclusion of ORPATHYS in China NRDL
AnnouncementRCS - Hutchmed China Ltd - FRUZAQLA® Launched in Japan by Takeda
AnnouncementREG - Hutchmed China Ltd - Appointment of Independent Non-executive Director
AnnouncementRCS - Hutchmed China Ltd - Clinical Data to be Presented at ASH and ESMO Asia
AnnouncementREG - Hutchmed China Ltd - Total Voting Rights
AnnouncementRCS - Hutchmed China Ltd - First Commercial Milestone Payment
AnnouncementREG - Hutchmed China Ltd - Vesting of awards under the LTIP
AnnouncementREG - Hutchmed China Ltd - SAVANNAH: clinically meaningful response rate
AnnouncementREG - Hutchmed China Ltd - Japan Approval for FRUZAQLA
AnnouncementRCS - Hutchmed China Ltd - Clinical Data to be Presented at ESMO and WCLC
Announcement